Interstitial Cystitis - Epidemiology Forecast to 2030

DelveInsight’s ‘Interstitial Cystitis (IC) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Interstitial Cystitis (IC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Interstitial Cystitis (IC) Understanding
Interstitial Cystitis (IC), also called as Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. Bladder is a hollow, muscular organ that stores urine. The bladder expands until it is full and then gives signals to the brain that it is time to urinate, communicating through the pelvic nerves. This creates the urge to urinate for most people. With IC, these signals get mixed up and then patients feel the need to urinate more often and with smaller volumes of urine than most people. The IC disease most often affects women and can have a long-lasting impact on the quality of life. Although there is no cure, medications and other therapies may offer some relief.

Types of Interstitial Cystitis
Interstitial Cystitis can be of two types:
1) Non-Ulcerative: It is found in 90% of the population suffering from Interstitial Cystitis. It is characterized by pinpoint hemorrhages called as glomerulations.
2) Ulcerative: About 5%-10% of the patient population suffers from this form of Interstitial Cystitis. It is mainly characterized by Hunner’s ulcers and the patches that bleed on bladder walls. Hunner’s ulcers, also called “Hunner’s lesions” or “Hunner’s patches,” are a subtype of Interstitial Cystitis (also called IC) and are not ulcers in the usual sense. They are distinctive areas of inflammation on the bladder wall that characterize the “classic” form of IC. Hunner’s ulcers are the one diagnostic feature that clinches the IC diagnosis, but this “classic” form of IC affects only about 5 to 10 percent of patients. Often, patients with this form of IC have more severe symptoms than patients with non-ulcerative IC.

To check for Hunner’s ulcers, physicians perform a procedure called cystoscopy. The physician uses a cystoscope to look inside bladder. It is important to note that Hunner’s ulcers are different from glomerulations, which are also often present in IC patients. Glomerulations are pinpoint-sized areas of bleeding in the bladder wall. Unlike Hunner’s ulcers, glomerulations do not automatically lead to a diagnosis of IC.

Treating Hunner’s ulcers themselves can reduce symptoms significantly. Physician can use one of these procedures to do so:
• Fulguration: “burning off” the ulcers by using a special instrument with a heated tip or a laser technique.
• Resection of ulcers: cutting around and removing the ulcers from the bladder wall.
• Submucosal injection: injecting a steroid (triamcinolone or Kenalog) into the ulcer. Although still being researched, this procedure can be safer and may prove to be as effective as the other two.
All these procedures are done while patient is under general or spinal anesthesia.

Interstitial Cystitis (IC) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Interstitial Cystitis (IC), Gender-specific Prevalent Population of Interstitial Cystitis (IC), Total Diagnosed Prevalent Population of Interstitial Cystitis (IC), Severity-based Diagnosed Prevalent Population of Interstitial Cystitis (IC), Type-specific Diagnosed Prevalent Population of Interstitial Cystitis (IC) and Age-specific Diagnosed Prevalent Population of Interstitial Cystitis (IC) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Interstitial Cystitis (IC) Detailed Epidemiology Segmentation
• The total diagnosed prevalent population of Interstitial Cystitis in the 7 major markets was found to be 2,264,118 in 2017. In case of Interstitial Cystitis patients in the United States, the diagnosed prevalent cases was found to be 1,459,502 in 2017.
• The prevalent population of Interstitial Cystitis in the United States was found to be 5,838,009 in 2017.
• DelveInsight has analyzed severity-based data for Interstitial Cystitis. Interstitial Cystitis can be divided as three types based on this data, namely, mild, moderate and severe type. It was found that in the United States the number of cases of mild, moderate and severe were 525,421, 729,751 and 204,330 respectively in 2017.
• Type-specific data for Interstitial Cystitis has also been analyzed by Delvelnsight. Interstitial Cystitis can be divided as two types based on this data, namely, Non-ulcerative and Ulcerative type. It was found that in the United States the number of cases of non-ulcerative and ulcerative type of IC were 1,313,552 and 145,950 respectively in 2017.
• In Japan, the diagnosed prevalence of Interstitial Cystitis was found to be 151,513 in 2017.

Scope of the Report
• The report covers the descriptive overview of Interstitial Cystitis (IC), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Interstitial Cystitis (IC).
• The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Prevalent Population of Interstitial Cystitis (IC) and Severity-based Diagnosed Prevalent Population of Interstitial Cystitis (IC).

Report Highlights
• Eleven Year Forecast of Interstitial Cystitis (IC)
• 7MM Coverage
• Total Diagnosed Prevalent Population of Interstitial Cystitis (IC)
• The report contains Gender-specific prevalence of IC in the 7MM, wherein females are found to suffer more as compared to male.
• Report also covers Severity-based Diagnosed Prevalent Population of Interstitial Cystitis, including several mild, moderate and severe IC.
• DelveInsight has also estimated Type-specific Diagnosed Prevalent Population of Interstitial Cystitis, comprising of Non-ulcerative and Ulcerative types. It was found that the Non-ulcerative is more prevalent across the 7MM.
• The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Interstitial Cystitis, wherein various age groups have been considered, such as 18–35, 36–55, 56–74 and 75+. It has been found that IC majorly affects patients whose age is 40 years or above.
• The current US market of IC is mainly dominated by the use of monotherpies and combination therapies.
• As per DelveInsight, there are several upcoming therapies targeting specific IC patient pool, such as Kyorin Pharmaceutical, UCB Pharma, Lipella Pharmaceuticals, Grünenthal and Astellas Pharma. Kyorin Pharmaceutical is developing KRP-116D, which has completed phase III trial and is expected to enter the market soon. It has shown improvements in IC/BPS symptoms, bladder pain and voiding parameters. On the other hand, Certolizumab pegol (Cimzia) by UCB Pharma has also completed phase III trial in the US and has demonstrated an acceptable safety profile for treating IC/BPS due to occurrence of microbiologically documented urinary infection in patients.

Key Questions Answered
• What is the disease risk, burden and unmet needs of Interstitial Cystitis (IC)?
• What is the historical Interstitial Cystitis (IC) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Interstitial Cystitis (IC) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Interstitial Cystitis (IC)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Interstitial Cystitis (IC) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The Interstitial Cystitis (IC) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Interstitial Cystitis (IC) market.
• Quantify patient share distribution in the 7MM for Interstitial Cystitis (IC).
• The Interstitial Cystitis (IC) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Interstitial Cystitis (IC) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1 Key Insights
2 Interstitial Cystitis Market Overview at a Glance
3 Interstitial Cystitis (IC): Disease Background and Overview
3.1 Introduction
3.2 Causes
3.3 Risk Factors
3.4 Signs and Symptoms
3.5 Pathophysiology
3.6 Diagnosis
3.6.1 Physical examination
3.6.2 Ultrasound/pelvic imaging
3.6.3 Frequency volume chart +/− post-void residual
3.6.4 Laboratory tests: Urinalysis, culture, cytology
3.6.5 Symptom scores
3.6.6 Cystoscopy
3.6.7 Potassium sensitivity test
3.6.8 Intravesical anesthetic bladder challenge
3.6.9 Hydrodistension
3.6.10 Urodynamics (UDS)
3.6.11 Bladder biopsy
3.7 Diagnostic Guidelines for IC/BPS by American Urology Association (AUA)
3.8 Biomarkers for patients with interstitial cystitis
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 G6 Total Prevalent Population of Interstitial Cystitis
4.3 7MM Total Diagnosed Prevalent Population of Interstitial Cystitis
5 Country-Wise Epidemiology of Interstitial Cystitis Syndrome
5.1 United States
5.1.1 Assumptions and Rationale
5.1.2 Total Prevalent Population of Interstitial Cystitis in the United States
5.1.3 Gender-specific Prevalent Population of Interstitial Cystitis in the United States
5.1.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in the United States
5.1.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in the United States
5.1.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States
5.1.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States
5.2 EU5 Countries
5.2.1 Assumptions and Rationale
5.3 Germany
5.3.1 Assumptions and Rationale
5.4 Germany
5.4.1 Total Prevalent Population of Interstitial Cystitis in Germany
5.4.2 Gender-specific Prevalent Population of Interstitial Cystitis in Germany
5.4.3 Total Diagnosed Prevalent Population of Interstitial Cystitis in Germany
5.4.4 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Germany
5.4.5 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany
5.4.6 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany
5.5 France
5.5.1 Assumptions and Rationale
5.5.2 Total Prevalent Population of Interstitial Cystitis in France
5.5.3 Gender-specific Prevalent Population of Interstitial Cystitis in France
5.5.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in France
5.5.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in France
5.5.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in France
5.5.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in France
5.6 Italy
5.6.1 Assumptions and Rationale
5.6.2 Total Prevalent Population of Interstitial Cystitis in Italy
5.6.3 Gender-specific Prevalent Population of Interstitial Cystitis in Italy
5.6.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in Italy
5.6.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Italy
5.6.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy
5.6.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy
5.7 Spain
5.7.1 Assumptions and Rationale
5.7.2 Total Prevalent Population of Interstitial Cystitis in Spain
5.7.3 Gender-specific Prevalent Population of Interstitial Cystitis in Spain
5.7.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in Spain
5.7.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Spain
5.7.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain
5.7.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain
5.8 United Kingdom
5.8.1 Assumptions and Rationale
5.8.2 Total Prevalent Population of Interstitial Cystitis in the United Kingdom
5.8.3 Gender-specific Prevalent Population of Interstitial Cystitis in the United Kingdom
5.8.4 Total Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom
5.8.5 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom
5.8.6 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom
5.8.7 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom
5.9 Japan
5.9.1 Assumptions and Rationale
5.9.2 Total Diagnosed Prevalent Population of Interstitial Cystitis in Japan
5.9.3 Gender-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan
5.9.4 Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Japan
5.9.5 Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan
5.9.6 Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan
21 Appendix
21.1 Bibliography
21.2 Report Methodology
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight
Table 1: The National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) Criteria for Diagnosis of IC/BPS
Table 2: Differential Diagnosis of IC/BPS
Table 3: Potential bladder tissue biomarkers for the diagnosis of IC/BPS
Table 4: Potential urine and serum biomarkers for the diagnosis of IC/BPS
Table 5: Total Prevalent Population of Interstitial Cystitis in the 7MM (2017–2030)
Table 6: Total Diagnosed Prevalent Population of Interstitial Cystitis in the 7MM (2017–2030)
Table 7: Total Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Table 8: Gender-specific Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Table 9: Total Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Table 10: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Table 11: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Table 12: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Table 13: Total Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Table 14: Gender-specific Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Table 15: Total Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Table 16: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Table 17: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Table 18: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Table 19: Total Prevalent Population of Interstitial Cystitis in France (2017–2030)
Table 20: Gender-specific Prevalent Population of Interstitial Cystitis in France (2017–2030)
Table 21: Total Diagnosed Prevalent Population of Interstitial Cystitis in France (2017–2030)
Table 22: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in France (2017–2030)
Table 23: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in France (2017–2030)
Table 24: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in France (2017–2030)
Table 25: Total Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Table 26: Gender-specific Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Table 27: Total Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Table 28: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Table 29: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Table 30: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Table 31: Total Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Table 32: Gender-specific Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Table 33: Total Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Table 34: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Table 35: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Table 36: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Table 37: Total Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Table 38: Gender-specific Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Table 39: Total Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Table 40: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Table 41: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Table 42: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Table 43: Total Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Table 44: Gender-specific Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Table 45: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Table 46: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Table 47: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Figure 1: Causes of Interstitial Cystitis
Figure 2: Risk Factors for Interstitial Cystitis
Figure 3: Normal bladder transitional epithelium with glycosaminoglycan (GAG) layer covering transitional cells. Small blue circles represent bound water molecules, and wavy lines represent the protein backbone.
Figure 4: Pathophysiology for Interstitial Cystitis
Figure 5: Total Prevalent Population of Interstitial Cystitis in the 7MM (2017–2030)
Figure 6: Total Diagnosed Prevalent Population of Interstitial Cystitis in the 7MM (2017–2030)
Figure 7: Total Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Figure 8: Gender-specific Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Figure 9: Total Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Figure 10: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Figure 11: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Figure 12: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United States (2017–2030)
Figure 13: Total Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Figure 14: Gender-specific Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Figure 15: Total Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Figure 16: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Figure 17: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Figure 18: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Germany (2017–2030)
Figure 19: Total Prevalent Population of Interstitial Cystitis in France (2017–2030)
Figure 20: Gender-specific Prevalent Population of Interstitial Cystitis in France (2017–2030)
Figure 21: Total Diagnosed Prevalent Population of Interstitial Cystitis in France (2017–2030)
Figure 22: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in France (2017–2030)
Figure 23: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in France (2017–2030)
Figure 24: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in France (2017–2030)
Figure 25: Total Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Figure 26: Gender-specific Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Figure 27: Total Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Figure 28: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Figure 29: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Figure 30: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Italy (2017–2030)
Figure 31: Total Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Figure 32: Gender-specific Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Figure 33: Total Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Figure 34: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Figure 35: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Figure 36: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Spain (2017–2030)
Figure 37: Total Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Figure 38: Gender-specific Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Figure 39: Total Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Figure 40: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Figure 41: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Figure 42: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in the United Kingdom (2017–2030)
Figure 43: Total Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Figure 44: Gender-specific Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Figure 45: Severity-based Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Figure 46: Type-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2017–2030)
Figure 47: Age-specific Diagnosed Prevalent Population of Interstitial Cystitis in Japan (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook